Arena rallies after partner announces broader coverage for Belviq Arena Pharmaceuticals (ARNA) partner Eisai announced earlier that it has secured improved patient access of weight loss drug Belviq with CVS Caremark (CVS) and Aetna (AET). CVS Caremark customers have broadened the coverage of Eisai's Belviq, according to Fingertip Formulary, a database of formulary information, the company said. Fingertip Formulary reports that depending on the design of the health plan or employer benefit, eligible CVS Caremark members may have access to Belviq in either a preferred or non-preferred brand position, it added. In addition, Fingertip Formulary states that the number of insured commercial lives in the United States with coverage for Belviq now exceeds 50%. Eisai added that Aetna recently announced that it would offer Belviq as a preferred brand to eligible patients as part of its pilot program to self-insured plan sponsors. Belviq is a registered trademark of Arena Pharmaceuticals (ARNA). Shares of Arena are up 5% to $6.28 in early afternoon trading.